The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | AutoSCT versus consolidation chemotherapy as post-remission treatment in newly diagnosed AML
Dimitrios Kotsos, MD, Erasmus MC, Rotterdam, Netherlands, discusses the findings of an analysis using data from two recent HOVON-SAKK-Nordic clinical trials, which compared autologous stem cell transplantation (autoSCT) to consolidation chemotherapy as post-remission treatment in newly diagnosed favorable- and intermediate-risk patients with acute myeloid leukemia (AML) in a measurable residual disease (MRD)-negative complete remission (CR). Dr Kotsos highlights that the study found similar relapse-free survival (RFS) and overall survival (OS) rates between the two groups, with some differences in adverse events, and suggests that chemotherapy may be the preferred option given the potential to add novel targeted agents. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
